Although only a few NSCLC cases are gefitinib-susceptible, responses to treatment with gefitinib may be linked to various mutations in the EGFR-TK domain, including the L834R mutation, which increases kinase activity. This evidence concerns the gene EGFR and non-small cell lung carcinoma.